Market revenue in 2023 | USD 296.9 million |
Market revenue in 2030 | USD 442.3 million |
Growth rate | 5.9% (CAGR from 2023 to 2030) |
Largest segment | Phase iii |
Fastest growing segment | Phase I |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Phase I, Phase II, Phase III, Phase IV |
Key market players worldwide | Novartis AG ADR, Labcorp Holdings Inc, Medpace Holdings Inc, Charles River Laboratories International Inc, Icon PLC, GlaxoSmithKline Consumer Healthcare (GSK CH India), Aurora Innovation Inc Class A, Biogen Inc, IQVIA Holdings Inc, inVentiv Health |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to neurology clinical trials market will help companies and investors design strategic landscapes.
Phase iii was the largest segment with a revenue share of 41.19% in 2023. Horizon Databook has segmented the UK neurology clinical trials market based on phase i, phase ii, phase iii, phase iv covering the revenue growth of each sub-segment from 2018 to 2030.
The market in the UK is lucrative owing to tax credits and expansion in developed countries. For instance, in the UK, there are two tax credits for large companies and small and medium-sized industries. Large companies can claim 30% deducible from the income of their R&D expenditure. In the case of small & medium-sized enterprises, it is 225% for R&D expenditure.
The UK’s success in early science has attracted investment & research activity by global pharmaceutical companies and famous universities & research centers in the country. The UK government has already committed to increase the GDP share spent on R&D to 2.4% by 2027 & to 3% by 2030.
The NHS has huge potential for driving global investment, and UK’s health service offers abundant opportunities for clinical trials of novel vaccines and medicines, with its wealth of expertise & access to health data. With healthcare data assets, competitive & collaborative research base, and substantial capabilities in clinical research & NHS translation, the UK has an attractive environment for clinical trials & pioneering research.
Horizon Databook provides a detailed overview of country-level data and insights on the UK neurology clinical trials market , including forecasts for subscribers. This country databook contains high-level insights into UK neurology clinical trials market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account